Cognitive Behavior Therapy for Insomnia: Analysis of Components, Mediators and Moderators

April 17, 2018 updated by: Markus Jansson-Fröjmark, Stockholm University
The overall purpose with this investigation is to further our knowledge about cognitive behavioral therapy (CBT) for insomnia by examining treatment components, mediators, and moderators. The first aim that will be addressed is to explore the efficacy of the CBT components with a dismantling-treatment strategy. Two active CBT interventions, intended to define its components - cognitive therapy and behavior therapy - will be compared with one another as well as with a waitlist condition on a broad range of outcomes at five to nine assessment points depending on the measures. The design will thus enable us to examine what CBT component or components are necessary, sufficient and facilitative of therapeutic change. The second aim that will be explored is to investigate what processes occur in CBT that may contribute to treatment outcome with a treatment-mediator strategy. To examine mediators for CBT, the following mediators will be assessed; Anxiety and Preoccupation about sleep Questionnaire (APSQ), Dysfunctional Beliefs and Attitudes about Sleep (DBAS), Sleep Associated Monitoring Index (SAMI), Sleep-Related Behavior Questionnaire (SRBQ), time in bed, napping, bedtime variability, and rise time variability. The hypothesis is that cognitive processes will mediate cognitive therapy outcomes, and that behavioral factors will have a mediating role for behavior therapy improvements. The third aim that will be addressed is to examine what patient characteristics does CBT depend on to be effective with a treatment-moderator strategy. To investigate moderators for CBT, the following moderators will be assessed; age, gender, occupational status, level of education, initial insomnia severity, dysfunction, medication use, chronic pain, psychiatric co-morbidity, medical co-morbidity, behavioral and cognitive processes used as mediators will also be employed as moderators.

Study Overview

Study Type

Interventional

Enrollment (Actual)

219

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Stockholm, Sweden
        • Stockholm University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Presence of insomnia more than three nights per week and for more than three months.
  • Insomnia despite adequate opportunity to sleep.
  • Insomnia severity typical for insomnia disorder, i.e. 11 points or more on the Insomnia Severity Index (ISI).
  • Nighttime insomnia symptoms, i.e., two points or more on at least one of the first three ISI questions.
  • Daytime insomnia symptoms, i.e. two points or more on one or both of the ISI distress and impairment items (numbers 5 and 7).
  • Clinical insomnia symptoms from sleep diaries concerning three nighttime symptoms (difficulties with sleep initiation, difficulties with sleep maintenance, and early morning awakenings), i.e., thirty minutes or more on average on one or more of the symptoms.
  • No current or past CBT-I treatment within the past 5 years.
  • Time and opportunity to participate in treatment for ten weeks.
  • Time and opportunity to read approximately fifteen pages per week and execute homework assignments for ten weeks.
  • Access to a computer, email and internet.

Exclusion Criteria:

  • Severe depression, i.e., more than 30 points on MADRS-S.
  • Suicidal risk, i.e., 4 points or more on item 9 on MADRS-S.
  • A high intake of alcohol or caffeine,
  • Insomnia due to shiftwork or other sleep-disturbing events (e.g., pregnancy, small children, or animals in the sleep environment).
  • Participants with a history of psychotic or bipolar disorder.
  • If a somatic condition is reported, it is required that it is relatively stable and/or that the candidate is receiving treatment for the condition.
  • When a candidate fulfills criteria for a psychiatric or somatic condition, it is required that insomnia is the disorder currently most distressing and disabling or that the insomnia remains despite treatment for the comorbid condition.
  • Participants with the following primary sleep disorders will be excluded via the Duke Structured Interview for Sleep Disorders (DSISD): sleep apnea, restless legs syndrome, periodic limb movement disorder, circadian rhythm disorder, and parasomnias.
  • If sleep medication is used, it is required that the use has been relatively stable during three months.
  • If Selective Serotonin Reuptake Inhibitors (SSRI) use is reported, it is required that the onset of the medication was at least three months prior to the telephone interview.
  • Participants who regularly consume sleep-disturbing medications.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: Behavior Therapy
Behavior Therapy involves the use of stimulus control and sleep restriction in order to reverse maladaptive sleep habits (time in bed, napping, bedtime variability, rise time variability) proposed to maintain insomnia. It also involves the practice of sleep hygiene principles.
EXPERIMENTAL: Cognitive Therapy
Cognitive Therapy involves challenging negative automatic thoughts about sleep and the use of behavioral experiments to challenge and test five cognitive processes (i.e., worry, dysfunctional thoughts, monitoring, safety behaviours, misperception) proposed to perpetuate insomnia.
OTHER: Waitlist
The waitlist serves as a passive control which will receive the same measures administered to the cognitive and behaviour therapy groups.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Changes on the insomnia severity index (ISI).
Time Frame: Pretreatment (week 0), during treatment (i.e., at week: 2, 4, 6, 8), post-treatment (week 10) and follow-up at 6, 12, and 18 month after treatment.
Pretreatment (week 0), during treatment (i.e., at week: 2, 4, 6, 8), post-treatment (week 10) and follow-up at 6, 12, and 18 month after treatment.

Secondary Outcome Measures

Outcome Measure
Time Frame
Changes on the Work and Social Adjustment Scale (WSAS).
Time Frame: Pretreatment (week 0), post-treatment (week 10) and follow-up at 6, 12, and 18 month after treatment.
Pretreatment (week 0), post-treatment (week 10) and follow-up at 6, 12, and 18 month after treatment.
Changes in sleep onset latency (SOL).
Time Frame: Pretreatment (week 0), during treatment (week: 2, 4, 6, 8) and post-treatment (week 10).
Pretreatment (week 0), during treatment (week: 2, 4, 6, 8) and post-treatment (week 10).
Changes in wake time after sleep onset (WASO).
Time Frame: Pretreatment (week 0), during treatment (week: 2, 4, 6, 8) and post-treatment (week 10).
Pretreatment (week 0), during treatment (week: 2, 4, 6, 8) and post-treatment (week 10).
Changes in early morning awakenings (EMA).
Time Frame: Pretreatment (week 0), during treatment (week: 2, 4, 6, 8) and post-treatment (week 10).
Pretreatment (week 0), during treatment (week: 2, 4, 6, 8) and post-treatment (week 10).
Changes in total sleep time (TST).
Time Frame: Pretreatment (week 0), during treatment (week: 2, 4, 6, 8) and post-treatment (week 10).
Pretreatment (week 0), during treatment (week: 2, 4, 6, 8) and post-treatment (week 10).
Changes in Hospital Anxiety and Depression Scale (HADS)
Time Frame: Pretreatment (week 0), post-treatment (week 10) and follow-up at 6, 12, and 18 month after treatment.
Pretreatment (week 0), post-treatment (week 10) and follow-up at 6, 12, and 18 month after treatment.
Changes in nighttime symptoms, by using item 1 - 3 from the primary outcome measure.
Time Frame: Pretreatment (week 0), during treatment (week: 2, 4, 6, 8), post-treatment (week 10) and follow-up at 6, 12, and 18 month after treatment.
Pretreatment (week 0), during treatment (week: 2, 4, 6, 8), post-treatment (week 10) and follow-up at 6, 12, and 18 month after treatment.
Changes in impairment, by using item 5 and 6 from the primary outcome measure.
Time Frame: Pretreatment (week 0), during treatment (week: 2, 4, 6, 8), post-treatment (week 10) and follow-up at 6, 12, and 18 month after treatment.
Pretreatment (week 0), during treatment (week: 2, 4, 6, 8), post-treatment (week 10) and follow-up at 6, 12, and 18 month after treatment.
Changes in distress, by using item 4 and 7 from the primary outcome measure.
Time Frame: Pretreatment (week 0), during treatment (week: 2, 4, 6, 8), post-treatment (week 10) and follow-up at 6, 12, and 18 month after treatment.
Pretreatment (week 0), during treatment (week: 2, 4, 6, 8), post-treatment (week 10) and follow-up at 6, 12, and 18 month after treatment.
Changes in Brunnsviken Brief Quality of life index (BBQ)
Time Frame: Pretreatment (week 0), post-treatment (week 10) and follow-up at 6, 12, and 18 month after treatment.
Pretreatment (week 0), post-treatment (week 10) and follow-up at 6, 12, and 18 month after treatment.

Other Outcome Measures

Outcome Measure
Time Frame
Credibility Expectancy Questionnaire (CEQ ).
Time Frame: During the first treatment module.
During the first treatment module.
Client Satisfaction Questionnaire (CSQ-8).
Time Frame: Post-treatment (week 10).
Post-treatment (week 10).
Activity and adherence with treatment protocol (self developed questionnaire assessing treatment activity and adherence relating to text, homework and therapist support).
Time Frame: Post-treatment (week 10).
Post-treatment (week 10).
Sick-leave and other concomitant treatment (self developed questionnaire).
Time Frame: Post-treatment (week 10).
Post-treatment (week 10).
Adverse events (questionnaire from a previous similar study).
Time Frame: Post-treatment (week 10).
Post-treatment (week 10).
Changes in physical activity (self developed questionnaire).
Time Frame: Pretreatment (week 0) and post-treatment (week 10).
Pretreatment (week 0) and post-treatment (week 10).
Changes in Ford Insomnia Response To Stress Test (FIRST).
Time Frame: Pretreatment (week 0) and post-treatment (week 10) for the waitlist.
Pretreatment (week 0) and post-treatment (week 10) for the waitlist.
Changes in Daytime Insomnia Symptom Response Scale (DISRS)
Time Frame: Pretreatment (week 0) and post-treatment (week 10) for the waitlist.
Pretreatment (week 0) and post-treatment (week 10) for the waitlist.
Montgomery Åsberg Depression Rating Scale (MADRS).
Time Frame: Pretreatment (week 0).
Pretreatment (week 0).
Changes in suicide risk (Item 9 from the MADRS).
Time Frame: Pretreatment (week 0), post-treatment (week 10) and follow-up at 6, 12, and 18 month after treatment.
Pretreatment (week 0), post-treatment (week 10) and follow-up at 6, 12, and 18 month after treatment.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Markus Jansson Fröjmark, PhD, Karolinska Institutet

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

August 1, 2016

Primary Completion (ACTUAL)

November 1, 2017

Study Completion (ACTUAL)

November 1, 2017

Study Registration Dates

First Submitted

November 21, 2016

First Submitted That Met QC Criteria

December 6, 2016

First Posted (ESTIMATE)

December 7, 2016

Study Record Updates

Last Update Posted (ACTUAL)

April 19, 2018

Last Update Submitted That Met QC Criteria

April 17, 2018

Last Verified

April 1, 2018

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Sleep Initiation and Maintenance Disorders

Clinical Trials on Behavior Therapy

3
Subscribe